Companies › Anhui Zhifei Longcom Biologic Pharmacy
6 active drug programs in 7 registered trials: 4 Phase 1, 2 Phase 3, 1 Phase 4; Infectious disease, Oncology; next expected readout Mar 2027.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| Mycobacterium Vaccae for Injection Live attenuated Mycobacterium vaccae vaccine | – | Phase 4 | Latent Tuberculosis Infection | Aug 2027 |
| quadrivalent recombinant norovirus vaccine (Pichia pastoris) Recombinant norovirus VP1 capsid proteins (GI.1, GII.3, GII.4, GII.17) | NOROVIRUS | Phase 3 | Acute Gastroenteropathy Due to Norovirus | Mar 2027 |
| BCG for Therapeutic Use Live attenuated Mycobacterium bovis vaccine strain | – | Phase 3 | BCG | Apr 2028 |
| Recombinant herpes zoster vaccine (ZFA01 adjuvant, CHO cells) - Low-dose Recombinant varicella-zoster virus glycoprotein E (50 μg) with ZFA01 adjuvant (375 μg) | – | Phase 1 | Herpes Zoster | May 2029 |
| BCG-PPD BCG-PPD skin test antigen for tuberculosis diagnosis | – | Phase 1 | Tuberculosis | – |
| Influenza Vaccine (Split Virion), Inactivated, Quadrivalent, ZFA02 Adjuvant Inactivated quadrivalent influenza vaccine with ZFA02 adjuvant | – | Phase 1 | Influenza, Human | – |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT04538911 | BCG-PPD | Phase 1 | Tuberculosis | Infectious disease | May 2023 |
| NCT06824519 | Influenza Vaccine (Split Virion), Inactivated, Quadrivalent, ZFA02 Adjuvant | Phase 1 | Influenza, Human | Infectious disease | Aug 2025 |
| NCT06524947 | quadrivalent recombinant norovirus vaccine (Pichia pastoris) | Phase 3 | Acute Gastroenteropathy Due to Norovirus | Infectious disease | Mar 2027 |
| NCT05680415 | Mycobacterium Vaccae for Injection | Phase 4 | Latent Tuberculosis Infection | Infectious disease | Aug 2027 |
| NCT06747455 | BCG for Therapeutic Use | Phase 3 | BCG | Oncology | Apr 2028 |
| NCT07920172 | Recombinant herpes zoster vaccine (ZFA01 adjuvant, CHO cells) - Low-dose | Phase 1 | Herpes Zoster | Infectious disease | May 2029 |
| NCT07920172 | Recombinant herpes zoster vaccine (ZFA01 adjuvant, CHO cells) - Low-dose | Phase 1 | Herpes Zoster | Infectious disease | May 2029 |
–
Aimei Vacin BioPharm (Zhejiang) Institut Pasteur CanSino Biologics MAXVAX Biotechnology Limited Liability Company InventVacc Biologicals
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.